Orion Begins Phase 1 Trial of ODM-216, Its First Clinical Biologic
Orion has begun a Phase 1 trial of ODM-216, its first biologic drug to enter clinical development.
Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
1 result loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Orion has begun a Phase 1 trial of ODM-216, its first biologic drug to enter clinical development.